Insight ReportWhat the Ozempic Economy Means for US Retail Anand Kumar, Associate Director of Retail Research Sector Lead: Swarooprani Muralidhar, Director of Research November 20, 2023 Reasons to ReadOzempic, a medication used to treat type 2 diabetes, is gaining strong momentum in the pharmaceutical market due to its ability to manage blood sugar levels and promote weight loss. The increased adoption of Ozempic and other drugs in the GLP-1 drug class reflects a broader consumer shift toward prioritizing health and wellness. We dive into the implications of widespread GLP-1 drug use on US retail, including the impacts on sectors such as grocery and apparel. Companies mentioned in this report include: Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, Walmart Other relevant research: Weinswig’s Weekly: Health Is Wealth Market Navigator: US Apparel and Footwear Retailing—After the Bounce, What’s Next? Generative AI for US Retail Pharmacies and Healthcare: Satisfying Customers through Automation and Personalization Visit the Coresight Research Food, Grocery and CPG Retail Hub to explore sector data, reports and company profiles. Already a subscriber? Log in You are currently viewing a preview of this report. Please select an access option to view the full report. Hide Options - Show Options + Get unlimited access to all our research with one of our subscription plans. View Subscription Plans or Contact us to purchase this report. Contact us ✕ This document was generated for Other research you may be interested in: The New Coresight 100: Leading the Retail Charge in 2025—InfographicDeepSeek: The Chinese AI Startup That Has Overtaken ChatGPT on Apple’s App StoreThree Data Points We’re Watching This Week, Week 12: US Retail and Consumer LatestShoptalk Fall 2025 Wrap-Up: Driving Retail Forward—AI, Agility, Loyalty and Leadership in Volatile Times
